Related Experiment Videos
Papillomavirus vaccines in clinical trials
1Division of Human Biology at the Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. dgallowa@fhcrc.org <dgallowa@fhcrc.org>
The Lancet. Infectious Diseases
|August 7, 2003
Summary
Human papillomaviruses (HPVs) cause cervical cancer, presenting a significant public health challenge. Understanding HPV pathogenesis and immune responses offers hope for eliminating HPV-associated diseases through vaccines.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Cervical cancer is a major cause of death in developing nations.
- Preneoplastic cervical lesions pose a public health burden in developed countries.
- Human papillomaviruses (HPVs) are unequivocally linked to cervical and anogenital cancers.
Purpose of the Study:
- To highlight the role of HPV in cervical cancer development and progression.
- To discuss the potential of prophylactic and therapeutic vaccines against HPV.
- To emphasize the importance of understanding HPV molecular pathogenesis and immune responses.
Main Methods:
- Review of evidence linking HPV to cervical malignancies.
- Discussion of ongoing clinical trials for HPV vaccines.
- Exploration of molecular pathogenesis and immune response strategies.
Main Results:
- Continued expression of HPV antigens drives neoplastic progression.
- Prophylactic and therapeutic HPV vaccines are in clinical trials.
- Understanding HPV natural history and immune triggers is crucial.
Conclusions:
- The viral etiology of cervical cancer presents a target for intervention.
- Vaccines offer a promising strategy for preventing and treating HPV-associated diseases.
- Further research into HPV pathogenesis and immunity may lead to disease elimination.